Trospium Chloride Dosing and Clinical Considerations
Trospium chloride should be dosed as 60 mg once daily in the morning on an empty stomach (at least 1 hour before meals) for adults with normal to moderate renal function, but is NOT recommended for patients with severe renal impairment (CrCl <30 mL/min). 1
Dosing by Renal Function
Standard Dosing
- 60 mg extended-release capsule once daily in the morning
- Must be taken with water on an empty stomach
- At least 1 hour before any meal 1
Renal Impairment Considerations
- Severe renal impairment (CrCl <30 mL/min): Trospium extended-release is contraindicated 1
- This is critical because trospium is primarily excreted unchanged in the urine as the active parent compound 2, 3
- No dosage adjustment needed based on age or sex alone 3
Absolute Contraindications
Trospium is contraindicated in patients with: 1
- Urinary retention
- Gastric retention
- Uncontrolled narrow-angle glaucoma
- Known hypersensitivity (angioedema, rash, anaphylaxis have been reported)
- Severe renal impairment (CrCl <30 mL/min)
Use with Extreme Caution
Per AUA/SUFU guidelines, anti-muscarinics like trospium should be used with extreme caution in: 4
- Patients with impaired gastric emptying (obtain gastroenterology clearance first)
- History of urinary retention (check post-void residual; obtain urology clearance)
- Patients taking solid oral potassium chloride (reduced gastric emptying increases potassium absorption risk)
For controlled narrow-angle glaucoma, use only if benefits outweigh risks and with careful ophthalmologic monitoring 1
Common Side Effects
The most frequent adverse effects are: 1, 5, 6, 7
Anticholinergic effects (class-related):
- Dry mouth (10.7-12.9% vs 3-4.6% placebo) - most common
- Constipation (7.5-9.4% vs 1.3-1.8% placebo)
- Dyspepsia
- Blurred vision
- Dry eyes
Notable advantage: CNS anticholinergic effects are rare with trospium due to its quaternary ammonium structure that minimally crosses the blood-brain barrier 2, 3, 7:
- Dizziness: 0.2% (vs 1.0% placebo)
- Headache: 1.4% (vs 2.4% placebo)
- Confusion, hallucinations, somnolence are uncommon
Critical Safety Warnings
Angioedema Risk
- Can occur after first dose
- If tongue, hypopharynx, or larynx involvement occurs, discontinue immediately and secure airway 1
CNS Monitoring
- Monitor for anticholinergic CNS effects, particularly after initiation or dose increases
- Advise patients not to drive or operate heavy machinery until they know how the medication affects them
- Consider dose reduction or discontinuation if CNS effects occur 1
Alcohol Interaction
- Alcohol should not be consumed within 2 hours of trospium administration
- Alcohol may enhance drowsiness from anticholinergic agents 1
Clinical Context
Trospium is recommended as second-line therapy for overactive bladder per AUA/SUFU guidelines, after behavioral therapies (bladder training, pelvic floor exercises, fluid management) have been attempted 4. It has no demonstrated superiority over other oral anti-muscarinics (darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine) in terms of efficacy, though its unique pharmacokinetic profile—minimal hepatic metabolism via CYP450 and predominantly renal excretion—may offer advantages in patients with hepatic dysfunction or multiple drug interactions 2, 3.